This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept
Pandemic response
COVID-19 is impacting communities around the world. PATH and our partners are responding.

Practical guidance for DMPA-SC introduction and scale-up

June 18, 2018 by PATH

Family planning leaders can draw from an established base of evidence to integrate DMPA-SC in efforts to address unmet need and increase access to contraception through a range of delivery channels.

Community health worker holds subcutaneous DMPA device (DMPA-SC, Sayana Press)

A community health worker holds the injectable contraceptive, DMPA-SC (brand name Sayana® Press). Photo: PATH/Will Boase

DMPA-SC* (brand name Sayana® Press) is now available in at least 20 Family Planning 2020 countries. Based on the first country introductions, PATH has developed practical guidance for ministries of health, nongovernmental implementing partners, and policymakers working to introduce and scale up DMPA-SC or similar products.

For more information, sign up for our newsletter or email FPoptions@path.org.

“Sayana Press is an easy method. For me as a provider, it is a method I like because it is all-in-one. … I take it, activate it and do the injection. It makes the work easier and I lose less time. In the end, Sayana Press gives me more time to spend with clients.”
— Midwife, Senegal

Resources

*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate.
Sayana Press is a registered trademark of Pfizer Inc.

Read More